ADHD Device Partnership Expanded Access
A new collaboration aims to increase availability of non-medication therapy options for children with ADHD.
Updated on Sept. 25, 2026 in Alzheimer’s
Live Poll
Do you support prioritizing non-drug therapies for children diagnosed with ADHD?
Firefly Neuroscience has partnered with NeuroSigma to expand access to the Monarch eTNS System, a non-drug treatment for pediatric ADHD. This collaboration seeks to bridge a significant treatment gap for the millions of U.S. children currently diagnosed with the condition.
Why it matters
Nearly one-third of the 6.5 million children with current ADHD in the U.S. receive no treatment, highlighting a need for alternatives to standard medication. This partnership integrates objective brain function insights to better connect clinicians and families with non-pharmacological options.
The partnership leverages Firefly's database of over 200,000 brain scans to support the Monarch eTNS System, an FDA-cleared device for children aged 7 through 12. While the device's efficacy is established for this age group, the impact of this specific integration remains to be seen.
The players
Firefly Neuroscience
A medical technology company specializing in AI-driven brain function insights and biomarker analysis.
NeuroSigma
A developer of non-invasive neuromodulation therapies, including the Monarch eTNS System for pediatric ADHD.
The details
The Monarch eTNS System delivers external trigeminal nerve stimulation via a small patch applied to the forehead during sleep. By integrating this with Firefly's Evoke platform, providers can utilize EEG and ERP biomarkers to gain objective insights into brain function. This data-driven approach aims to streamline the identification of patients who may benefit from non-drug interventions.
Timeline
March 2026: Firefly identified EEG/ERP biomarkers for ADHD presentations.
July 2026: NeuroSigma launched U.S. sales for the Monarch device.
September 2026: NeuroSigma expanded third-party installment payment options.
September 25, 2026: Firefly Neuroscience shares increased 42.01 percent.
Health Landscape
This development follows the recent FDA clearance of the Monarch eTNS System, marking a transition toward broader, data-supported integration in pediatric care. It addresses the ongoing industry shift to provide objective neurological data to support non-pharmaceutical treatment pathways.
Parents of children aged 7 through 12 who are exploring non-medication alternatives for ADHD may find it helpful to discuss whether this technology aligns with their child's care plan. Families should consult their pediatrician to determine if an objective brain function assessment is appropriate.
The takeaway
The partnership highlights an expanding landscape for digital health tools in managing pediatric ADHD. Caregivers should track new, FDA-cleared non-drug technologies and discuss their suitability during regular consultations with their child's physician.
Further reading
For more information on the management of neurodevelopmental conditions, visit our Alzheimer’s section.
Live Poll
Do you support prioritizing non-drug therapies for children diagnosed with ADHD?
